STAT Plus: New bill would create a subscription payment model to jumpstart antibiotic development
In a bid to combat antimicrobial resistance, two U.S. lawmakers have introduced a bipartisan bill that would create a new payment model to encourage drug makers to develop antibiotics.
Known as the Pasteur Act, the legislation would establish a subscription-style model to offer upfront payments to pharmaceutical companies in exchange for unlimited access to their antibiotics. The idea is to enable drug makers to recover their costs and make an appropriate profit without having to sell large volumes of antibiotics.